Find the Perfect Plan for Your Investment Journey
E
Latest price
52 Week Range
A$0.80 - A$4.97
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | A$73.83M |
EV | A$54.41M |
Shares Outstanding | 47.17M |
Beta | 0.42 |
Analyst Rating | NO_OPINION |
Analyst Target Price | A$5.15 |
P/E 2025E | 8.65x |
P/Revenue 2025E | 0.82x |
Revenue | 43.90% |
EPS | 39.30% |
Operating Cash Flow | 189.40% |
Free Cash Flow | - |
Revenue | 17.80% |
EPS | 15.60% |
Operating Cash Flow | 25.40% |
Free Cash Flow | 37.40% |
Gross Margin 2025E | 76.70% |
Net Profit Margin 2025E | 8.92% |
ROE 2025E | 27.30% |
ROCE 2024 | 38.79% |
DPS 2025E | A$0.04 |
Payout Ratio 2025E | 22.22% |
Div. Yield 2025E | 2.48% |
DPS Last 3Y CAGR | 98.10% |
Price
%
1M
3M
6M
1Y
3Y
5Y
E
EZZ Life Science Holdings Limited
EZZ
Sector
Healthcare
Industry
Biotechnology
CEO
Qin, Mark
Employees
Website
ezzlife.com.auIPO Date
2021-03-02
Headquarters
Shop 1, 55-59 Parramatta Rd, Lidcombe, New South Wales, 2141, Australia
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved